Increased levels of NAD(P)H: Quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas

Cell Biology and Toxicology

Volumn 22, Issue 2, 2006, Pages 73-80

  Lyn Cook, B D ^a,b   Yan Sanders, Y ^a   Moore, S ^a   Taylor, S ^a   Word, B ^a   Hammons, G J ^a  

^a National Center for Toxicological Research   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

NQO1; Pancreatic; Pancreatitis; Polymorphism; Smoking

Indexed keywords

BIOLOGICAL MARKER; CYTOSINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THYMINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PANCREAS INJURY; PANCREATITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NAD(P)H DEHYDROGENASE (QUINONE); PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 33644851998     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-006-0156-3     Document Type: Article

References (37)

1. Anderson KE, Mammons GJ, Kadlubar FF, et al. Metabolic activation of aromatic amines by human pancreas. Carcinogenesis. 1997;18:1085-92.
2. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastronenterology. 1995;109:247-51.
3. Bouvet M, Binmoeller KF, Moossa AR. Diagnosis of adenocarcinoma of the pancreas. In: Cameron JL, ed. American Cancer Society atlas of clinical oncology: pancreatic cancer. Hamilton, Ontario: BC Decker;2001.
4. Chang W-C, Lee Y-C, Liu C-L, et al. Increased expression of iNOS and c-fos via regulation of protein tyrosine phosphorylation and MEK1/ERK2 proteins in terminal bronchiole lesions in the lungs of rats exposed to cigarette smoke. Arch Toxicol. 2001;75:28-35.
5. 609C→T polymorphism with a decreased lung cancer risk. Cancer Res. 1999;59:3045-8.
6. Clairmont A, Sies H, Ramachandran S, et al. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with the numbers of basal cell carcinomas: use of a multi-variate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis (Lond). 1999;20:1235-40.
7. De Flora S, Bennicelli C, D'Agostini F, Izzotti A, Camoirano A. Cytosolic activation of aromatic and heterocyclic amines: inhibition by dicoumarol and enhancement in viral hepatitis B. Environ Health Perspect. 1994;6:69-74.
8. Dhakshinamoorthy S, Long DJ II, Jaiswal AK. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr Top Cellul Regul. 2000;36:201-6.
9. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766-92.
10. Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med. 1996;156:2255-60.
11. Hammons GJ, Warren GJ, Blann E, Nichols J, Lyn-Cook BD. Increased DT-diaphorase activity in transformed and tumorigenic pancreatic acinar cells. Cancer Lett. 1995;96:9-14.
12. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2002;52:23-47.
13. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76:852-4.
14. Koudstaal J, Makkink B, Overdiep SH. Enzyme histochemical pattern in human tumours. II. Oxidoreductases in carcinoma of the colon and the breast. Eur J Cancer. 1975;11:111-5.
15. Landi L, Fiorentini D, Galli MC, Segura-Aguilar J, Beyer RE. DT-diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function. Free Radical Biol Med. 1997;22:329-35.
16. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803-7.
17. Lin Y, Tamakoshi A, Kawamura T, et al. A prospective study of cigarette smoking and pancreatic cancer in Japan. Cancer Causes Control. 2002;13:249-54.
18. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63:2649-57.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall NJ. Protein measurement with the Polin phenol reagent. J Biol Chem. 1951;193:265-75.
20. Malkinson AM, Siegel D, Forrest GL, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res. 1992;52:4752-7.
21. Muller T. Expression of c-fos in quiescent Swiss 3T3 cell exposed to aqueous cigarette smoke fractions. Cancer Res. 1995;55:1927-32.
22. Nims RW, Prough RA, Lubet RA. Cytosol-mediated reduction of resorufin: a method for measuring quinone oxidoreductase. Arch Biochem Biophys. 1984;229:459-65.
23. Radjendirane V, Joseph P, Jaiswal AK. Gene expression of DT-diaphorase (NQO1) in cancer cells. In: Oxidative stress and signal transduction. New York: Chapman Hall; 1997: 441-75.
24. Ross D. Quinone reductases. In: Guengerich FP, Sipes IG, McQueen CA, Gandolfi AJ, eds. Vol. 3. New York: Elsevier; 1997:179-7.
25. Ross D, Seigel D, Geall H, Prakash AS, Mulcahy RT, Gibson NW. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev. 1993;12:83-101.
26. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H: quinone oxidoreductase polymorphorism and its association with lung cancer and smoking. Pharmacogenetics. 1995;5:199-206.
27. Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor form hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997;57:2839-42.
28. Schlager JJ, Powis G. Cystolic NAD(P)H:(quinone acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990;45:403-9.
29. Schor NA, Cornelisse, CJ. Biochemical and quantitative histochemical study of reduced pyridine nucleotide dehydrogenation by human colonie carcinomas. Cancer Res. 1983;43:4850-5.
30. Schulz WA, Krumeck A, Rosinger I, et al. Increased frequency of the null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235-9.
31. Siegel D, Anwar A, Winski SL, Kepa JK, Dowd KL, Ross D. Rapid polyubiquitination proteasomal degradation of a mutant form of NAD(P)H:quinonone oxidoreductase 1. Mol Pharmacol. 2001;59:263-8.
32. Steiner M, Hillenbrand M, Borkowsi M, Seiter H, Schuff-Werner P. 609 C→T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett. 1999;135:67-71.
33. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H: quinone oxidoreductase1 gene. Proc Natl Acad Sci USA. 1996;93:14960-5.
34. Vineis P, Caporaso N. Tobacco and cancer epidemiology and the laboratory. Environ Health Perspect. 1995;103:156-60.
35. Workman P. Enzyme-directed bioreductive drug development revisited. A commentary of recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes particularly DT-diaphorase. Oncol Res. 1994;6: 461-75.
36. Yao K-S, Hageboutros A., Ford P, O'Dwyer PJ. Involvement of activator protein-1 and nuclear factor-κB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. Mol Pharmacol. 1997;51:422-30.
37. Zhu S, Manuel M, Tanaka S, Choe N, Kagan E, Matalon S. Contribution of reactive oxygen and nitrogen species to particulate-induced lung injury. Environ Health Perspect. 1998;106: s1157-63.